Inhibition of Sodium-GlucoseCotransporter 2 with Dapagliflozin in Han: SPRD Rats with Polycystic Kidney Disease

Inhibition of Sodium-GlucoseCotransporter 2 with Dapagliflozin in Han: SPRD Rats with Polycystic Kidney Disease

Background/Aims: Dapagliflozin (DAPA) is a selective inhibitor of the sodium-glucose cotransporter 2 (SGLT2) which induces glucosuria and osmotic diuresis. The therapeutic effect of DAPA in progressing stages of polycystic kidney disease (PKD) has not been studied. Methods: We examined the effect of...

Full description

Bibliographic Details
Main Authors: Daniel Rodriguez, Sarika Kapoor, Ilka Edenhofer, Stephan Segerer, Meliana Riwanto, Anja Kipar, Ming Yang, Changlin Mei, Rudolf P. Wüthrich
Format: Article
Language:English
Published: Karger Publishers 2015-12-01
Series:Kidney & Blood Pressure Research
Subjects:
Dapagliflozin
Glucosuria
Polycystic kidney disease (PKD)
Sodium glucose cotransporter (SGLT)
Cyst
Online Access:http://www.karger.com/Article/FullText/368540

Internet

http://www.karger.com/Article/FullText/368540

Similar Items